EC Number   |
Natural Substrates |
|---|
   3.2.1.49 | blood group A glycoconjugate + H2O |
alpha-N-acetylgalactosaminidase blood group A2 degrading activity, substrate from human erythrocytes and plasma |
| 3.2.1.49 | more |
enzyme deficiency, due to missense mutations at residue R329 causing structural changes in the enzyme leading to differing substrate specificity, causes the Kanzaki disease, an autosomal recessine storage disorder with accumulation of GalNAcalpha1-O-Ser/Thr in the lysosome and increased urinary excretion of O-linked sialylglycopeptides, phenotype, overview |
| 3.2.1.49 | more |
the enzyme plays a dual role in regulating both infectivity and immunosuppression |
| 3.2.1.49 | more |
alpha-NAGAL is a lysosomal exoglycosidase that cleaves terminal alpha-N-acetylgalactosamine residues from glycopeptides and glycolipids |
| 3.2.1.49 | more |
the enzyme hydrolyzes alpha-N-acetylgalactosyl residues from glycolipids and glycoproteins |
| 3.2.1.49 | more |
an exoglycosidase specific for the hydrolysis of terminal alpha-linked N-acetylgalactosamine in various sugar chains |
| 3.2.1.49 | serum vitamin D3-binding protein + H2O |
i.e. Gc protein, the human substrate is the precursor of the principal macrophage activating factor, MAF, the deglycosylated prrecursor cannot be converted, which leads to immunosuppression |
